Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock popped more than 47% on…
